

<https://doi.org/10.1038/s41541-026-01470-4>

Author Correction: Production of an immunogenic trivalent poliovirus virus-like particle vaccine candidate in yeast using controlled fermentation

Check for updates

Lee Sherry, Keith Grehan, Mohammad W. Bahar, Jessica J. Swanson, Helen Fox, Sue Matthews, Sarah Carlyle, Ling Qin, Claudine Porta, Steven Wilkinson, Suzanne Robb, Naomi Clark, John Liddell, Elizabeth E. Fry, David I. Stuart, Andrew J. Macadam, David J. Rowlands & Nicola J. Stonehouse

Correction to: *npj Vaccines* <https://doi.org/10.1038/s41541-025-01111-2>, published online 31 March 2025

In the original article, Figure 6 was incorrect and mistakenly reported immunogenicity data in which the IPV control was also adjuvanted. Figure 6 has now been updated to include the correct immunogenicity data, comparing the virus-like particle vaccine candidates to IPV in the absence of adjuvant. The corresponding figure legend has also been corrected from ‘(*, p value > 0.05, **, p value > 0.01)’ to ‘(*, p value > 0.05, ***, p value > 0.001)’ to reflect the correct statistical analysis comparing the neutralising antibody titres for the virus-like particle vaccine candidates for each serotype to IPV in the absence of adjuvant.

Incorrect Figure 6




Fig. 6 Trivalent immunogenicity of PV rsVLPs. Dose response in neutralizing antibodies following a single immunization of Wistar rats with trivalent PV VLPs containing PV1-SC6b, PV2-SC5a and PV3-SC8 VLPs, in either the absence or presence of adjuvant. Groups of 10 rats received VLPs at various multiples of human doses and were compared to a group that had received IPV as a positive control. Sera were collected 21 dpi and

neutralisation titres against the Sabin strains of PV1, PV2 or PV3 were determined. Error bars represent the Geomean Standard Deviation of the data points. Statistical analysis determined by two-tailed t test in comparison to IPV (*, p value > 0.05, **, p value > 0.01). * colour denotes the comparison group.

Correct Figure 6




Fig. 6 Trivalent immunogenicity of PV rsVLPs. Dose response in neutralizing antibodies following a single immunization of Wistar rats with trivalent PV VLPs containing PV1-SC6b, PV2-SC5a and PV3-SC8 VLPs, in either the absence or presence of adjuvant. Groups of 10 rats received VLPs at various multiples of human doses and were compared to a group that had received IPV as a positive control. Sera were collected 21 dpi and

neutralisation titres against the Sabin strains of PV1, PV2 or PV3 were determined. Error bars represent the Geomean Standard Deviation of the data points. Statistical analysis determined by two-tailed t test in comparison to IPV (*, p value > 0.05, ***, p value > 0.001). * colour denotes the comparison group.

Published online: 29 May 2026

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2026